AI assistant
RHYTHM PHARMACEUTICALS, INC. — Director's Dealing 2025
May 1, 2025
30849_dirs_2025-05-01_71ba1ac0-04ad-42bc-b3a1-36435790754e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK: 0001649904
Period of Report: 2025-04-29
Reporting Person: Mazabraud Yann (EVP, Head of International)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-04-29 | Common Stock | S | 6745 | $65.0773 | Disposed | 37655 | Direct |
Footnotes
F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 13, 2024.
F2: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $65.00 to $65.22 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.